Thyroid antibodies, decoded.

The editorial TLDR.

What the antibodies actually are.

Antibodies are proteins the immune system makes to identify and neutralize foreign threats — viruses, bacteria, allergens. In autoimmune disease, the immune system makes antibodies directed at the body's own tissues instead. For the thyroid, three antibodies show up in clinical workups most often.

TPO antibodies (TPOAb). Thyroid peroxidase is the enzyme inside thyroid cells that builds thyroid hormone. TPO antibodies target this enzyme and, over years, gradually degrade the gland's ability to produce hormone. TPOAb is by a wide margin the most common autoimmune thyroid marker in U.S. women — present in roughly 90% of Hashimoto's cases and in a smaller proportion of Graves' cases. It often turns positive well before TSH moves out of range, sometimes by years.

Thyroglobulin antibodies (TgAb). Thyroglobulin is the storage protein inside thyroid follicles that holds thyroid hormone before release. TgAb is a second marker of autoimmune activity directed at the thyroid. It's present in roughly 80% of Hashimoto's cases, often alongside TPO. Some patients are TPO-negative but TgAb-positive — which is why the two are usually tested together in a comprehensive workup.

"TSH tells you what the thyroid is doing now. Antibodies tell you what the immune system is doing to it — often years earlier."

TSH receptor antibodies (TRAb). A different antibody, directed at the receptor that TSH binds to on the thyroid cell surface. There are two functional types: stimulating antibodies (TSI) that bind the receptor and activate it — producing the overactive thyroid pattern of Graves' disease — and blocking antibodies that interfere with the signal. TRAb is the defining lab marker for Graves' and is tested when overactive thyroid is suspected, in pregnancy with a Graves' history, or to monitor remission after treatment.

Standard U.S. labs measure these antibodies with immunoassays. Levels can range from just above the reference cutoff to hundreds of times the upper limit; the absolute number matters less than whether it is positive or negative, and how it tracks over time.

Why thyroid antibodies matter for women.

Autoimmune thyroid disease is overwhelmingly a women's-health condition. U.S. women are roughly 5–8 times more likely than men to develop Hashimoto's or Graves' disease across the lifespan. The patterns cluster in specific clinical windows where antibody testing is most informative.

Subclinical thyroid patterns. A TSH between 4.0 and 10 with a normal free T4 is what's often described as subclinical hypothyroidism. Whether to treat depends on multiple factors — symptoms, age, fertility goals, and, importantly, antibody status. American Thyroid Association guidance, ACOG and most endocrinology consensus statements treat antibody-positive subclinical hypothyroidism more aggressively than antibody-negative, particularly in pregnancy and pre-conception.

Fertility and pre-conception planning. Multiple studies have linked TPO positivity — even with normal TSH — to higher rates of miscarriage and slightly later achievement of pregnancy. The American College of Obstetricians and Gynecologists and the American Society for Reproductive Medicine both consider TPO antibody testing reasonable in women with infertility or recurrent pregnancy loss. The clinical conversation is evolving; the testing case is increasingly accepted.

Postpartum thyroiditis. Up to one in ten U.S. women develop postpartum thyroiditis in the first year after birth — a self-limited inflammatory swing of the thyroid, often from overactive into underactive. TPO positivity before or during pregnancy is the single strongest predictor of postpartum thyroiditis risk. Women with positive antibodies during pregnancy benefit from postpartum thyroid surveillance.

Family history. Autoimmune thyroid disease clusters in families. A woman with a mother, sister or daughter with Hashimoto's or Graves' is at meaningfully higher baseline risk. A baseline antibody check in adult life is reasonable conversation when family history is significant.

Other autoimmune conditions. Autoimmune diseases tend to travel together. Women with type 1 diabetes, celiac disease, vitiligo, rheumatoid arthritis or lupus have higher rates of co-existing autoimmune thyroid disease. Periodic thyroid screening — including antibodies — is part of integrated care for many of these patients.

Persistent symptoms with normal TSH. A common pattern: a woman in her late thirties or forties with fatigue, weight changes, hair shedding, brain fog and mood flatness. TSH comes back at 3.5 — "in range" by U.S. lab norms. A positive TPO antibody alongside that TSH meaningfully changes the clinical conversation, even when TSH alone would have been reassuring.

What the ranges generally mean.

Most U.S. labs report TPO and TgAb in IU/mL, with thresholds defined per assay. The broad framework below is common for non-pregnant adult women.

Illustrative ranges, not diagnostic. Cutoffs vary by laboratory and assay. The absolute number above the cutoff matters less than positive-versus-negative status and how it tracks. Always discuss your specific result with a qualified healthcare provider.

What may drive antibodies positive.

Antibody positivity is not random — it clusters with specific clinical contexts and genetic backgrounds.

What may drive TPO or TgAb positive.

• Hashimoto's thyroiditis. The most common autoimmune thyroid disease in U.S. women. TPO and TgAb together describe roughly 95% of cases. Often gradual, often years between antibody positivity and overt hypothyroidism.
• Graves' disease. Although TRAb is the defining marker, TPO is also positive in roughly 70% of Graves' cases.
• Postpartum thyroiditis. A self-limited inflammatory swing in the year after birth. TPO positivity before or during pregnancy is the strongest predictor.
• Family history. A strong family history of autoimmune thyroid or other autoimmune disease raises baseline risk meaningfully.
• Other autoimmune conditions. Type 1 diabetes, celiac disease, vitiligo, lupus, rheumatoid arthritis and pernicious anemia all cluster with autoimmune thyroid disease.
• Iodine status. Both iodine deficiency and iodine excess can be associated with autoimmune thyroid patterns. Iodine in supplements (often in "thyroid support" products) can drive antibody titers up in some women.
• Stress and life-event triggers. Pregnancy, postpartum, severe stress and viral illness can unmask underlying autoimmune predispositions.
• Smoking. Cigarette smoking is associated with Graves' disease (particularly Graves' orbitopathy); cessation supports remission.
• Genetic background. HLA and other immune-gene variants influence individual susceptibility.

What may drive TRAb positive.

• Graves' disease. The defining marker. TRAb (or TSI specifically) is positive in nearly all Graves' cases.
• Pregnancy in a woman with prior Graves'. TRAb crosses the placenta and can affect the fetal thyroid. The American Thyroid Association recommends TRAb testing in the second trimester for women with a Graves' history.
• Following radioiodine or thyroidectomy for Graves'. TRAb levels can rise transiently before falling and are tracked as part of remission monitoring.

Your provider will guide the conversation based on your full medical context. These prompts are designed to make sure thyroid antibodies are part of the workup in the clinical situations where they matter most.

When to test, and how it's measured.

Thyroid antibody testing is a standard venous blood draw, generally bundled with TSH, free T4 and (often) free T3. No fasting is required, and timing during the day matters minimally for antibodies themselves.

If you are taking high-dose biotin (often in hair, skin and nail supplements), pause it for at least 48 hours before the test — biotin can interfere with several thyroid immunoassays. Recent radiologic contrast (CT scans with iodinated dye), amiodarone treatment and certain other medications can shift the wider thyroid panel and are worth flagging.

When to test antibodies — situations where the evidence is strongest:

• Subclinical TSH elevation (4.0–10.0 mIU/L), particularly with symptoms or in pre-conception
• Family history of Hashimoto's, Graves' or other autoimmune disease
• Trying to conceive, particularly with prior miscarriage or fertility difficulty
• Postpartum, particularly with mood, energy or weight changes beyond 3–6 months
• Persistent thyroid-suggestive symptoms with TSH in the upper-normal range
• An existing autoimmune condition (type 1 diabetes, celiac, lupus, etc.)
• Pregnancy in a woman with prior Graves' disease (TRAb)

Direct-to-consumer at-home tests — Function Health, LetsGetChecked's comprehensive thyroid panels, Quest Health — include TPO and TgAb in their full thyroid offerings. They're useful for a baseline; they don't replace the clinical conversation about what to do with the result. For the trade-offs across services, see our guide to at-home blood tests for women.

Related biomarkers worth understanding.

Thyroid antibodies rarely sit alone in a thoughtful workup. The markers below come up most often alongside them.

• TSH — the first-line thyroid screen. Read antibodies and TSH together for the full autoimmune picture.
• Free T4 — the reservoir thyroid hormone. Distinguishes overt from subclinical patterns.
• Free T3 — the active hormone at the cellular level. Adds context to autoimmune patterns.
• Vitamin D — often low alongside autoimmune thyroid patterns. A baseline check is reasonable.
• Iron and ferritin — low iron is associated with impaired T4-to-T3 conversion and frequently coexists with Hashimoto's in women.
• Vitamin B12 — pernicious anemia (B12 deficiency from autoimmune gastritis) clusters with autoimmune thyroid disease.